论文部分内容阅读
目的:观察依达拉奉对放射性脑水肿的影响。方法:选择98例放射性脑水肿患者,随机分成治疗组50例和对照组48例,对照组给予20%甘露醇250mL静滴(q12h),地塞米松磷酸钠注射液10mg加入10%葡萄糖注射液500mL静滴(qd),疗程14d;治疗组在对照组治疗的基础上给予依达拉奉注射液30mg加入生理盐水注射液100mL静滴(bid),疗程14d。2组在治疗后均做脑部CT或MRI检查,按照脑部CT或MRI显示脑水肿最大层面的长×宽测算脑水肿的面积,以脑水肿的面积表示脑水肿的程度,观察脑水肿的变化。结果:治疗组的总有效率是92%,对照组的总有效率是65%,治疗组的总有效率明显优于对照组(P<0.01),2组均无明显不良反应。结论:依达拉奉可以减轻放射性脑水肿,且临床应用安全。
Objective: To observe the effect of edaravone on radiation brain edema. Methods: Ninety-eight patients with radioactive cerebral edema were randomly divided into treatment group (n = 50) and control group (n = 48). The control group was given intravenous infusion of 20% mannitol (q12h), dexamethasone sodium phosphate injection 500ml intravenous drip (qd) for 14 days. In the treatment group, edaravone 30mg was added to 100ml saline injection on the basis of the control group, and the course of treatment was 14 days. 2 groups were treated with CT or MRI brain examination, according to the brain CT or MRI showed the largest level of cerebral edema, the maximum width of the area of ?? brain edema, brain edema area to indicate the extent of cerebral edema, cerebral edema Variety. Results: The total effective rate of the treatment group was 92%, while the total effective rate of the control group was 65%. The total effective rate of the treatment group was significantly better than that of the control group (P <0.01). No significant adverse reactions were found in the two groups. Conclusion: Edaravone can reduce radiation-induced brain edema and its clinical application is safe.